Core Patent in Bioinformatic Algorithm

                            OriFusion, a competitive patent algorithm

                            1. Patent assures high-performance: With the unique technology of fusion model detection, OrigiMed’s patent algorithm can precisely identify the breakpoint location.
                            2. High sensitivity: By precisely positioning, OriFusion can capture low-frequency variants even in a poor-quality sample with a small number of tumor cells.
                            3. High detection rate: OriFusion has a globally competitive detection rate.
                            4. New fusion: OriFusion has a high detection rate of new gene fusions.

                            Illustration of driver genes and complicated
                            fusion models detected by OriFusion.

                            OriLongindel, the first Long-Indel algorithm for NGS

                            1. In January, 2019, OrigiMed obtained a patent on the first Chinese invention of long insertion/deletion (Long Indel) algorithm.
                            2. It accurately detects 50-3,000 bp insertion and deletion with 100% specificity.
                            3. It mapped Long-Indel mutations on the largest Chinese cohort (n=3,309).

                            Patent OriTMB Algorithm

                            1. In July, 2018, OrigiMed obtained a patent on the invention of OriTMB.
                            2. In August, 2019, its validation study was published in the world’s renowned journal, the Oncologist (IF: 5.3).
                            3. OriTMB’s result showed a high degree of concordance with TMB by WES (R=0.98).
                            4. TMB-H gastric cancer patients show an overall response rate (ORR) of 33.3% and overall survival of 14.6 months, compared with TMB-L patients with 33.3% ORR and 4.0 months OS.

                            OriMSI, a microsatellite instability algorithm validated
                            in a stringent and systematic way

                            1. Stringent validation for multiple cancers, showing an accuracy of 99.5%, sensitivity of 98.8%, and 99.7% of specificity.
                            2. Confirmed by triple validation of IHC, PCR, and Mantis (algorithm for NGS).
                            3. The correlation of MSI status with TMB showed that MSI-H patients had a higher TMB than MSS patients both for colorectal cancer and pan-cancer.